Episode-based payment for cancer care: a proposed pilot for Medicare.
暂无分享,去创建一个
[1] P. Bach,et al. Pem and the cost of multicycle maintenance. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] C. Earle,et al. How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. , 2010, Health affairs.
[3] M. Socinski,et al. Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] W. Wong,et al. Year one evaluation of regional pay for quality (P4Q) oncology program. , 2010 .
[5] P. Bach. Limits on Medicare's ability to control rising spending on cancer drugs. , 2009, The New England journal of medicine.
[6] S. Altman,et al. Payment reform options: episode payment is a good place to start. , 2009, Health affairs.
[7] R. Reischauer,et al. Collective accountability for medical care--toward bundled Medicare payments. , 2008, The New England journal of medicine.
[8] Elaine L. Towle,et al. Key practice indicators in office-based oncology practices: 2007 report on 2006 data. , 2007, Journal of oncology practice.
[9] J. Davila,et al. Receipt of Recommended Therapy by Patients with Advanced Colorectal Cancer , 2006, The American Journal of Gastroenterology.
[10] P. Bach. Using practice guidelines to assess cancer care quality. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Colin B Begg,et al. Adherence to surveillance among patients with superficial bladder cancer. , 2003, Journal of the National Cancer Institute.
[12] G. Scagliotti,et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Begg,et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. , 2001, Journal of the National Cancer Institute.
[14] Lonny Reisman,et al. Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. , 2010, Journal of oncology practice.
[15] Handra,et al. COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON–SMALL-CELL LUNG CANCER , 2001 .